ArticleDrug delivery and translational research2026
Strategic lipid nanoparticle design dictates retinal delivery post inner limiting membrane disruption.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Lipid nanoparticles enable mRNA delivery to diverse cell types of the inner Retina.Molecular therapy. Nucleic acids · 2026Article
- Strategic lipid nanoparticle design dictates retinal delivery post inner limiting membrane disruption.Drug delivery and translational research · 2026Article
- CRISPR-Cas9-Loaded Theranostic Liposomes for Enhancing Radiosensitization of Prostate Cancer through POLD4 Gene Editing under Real-Time MRI Monitoring.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Photodisruption of the Inner Limiting Membrane Promotes Retinal Engraftment of Stem-Cell Derived Retinal Ganglion Cells.Investigative ophthalmology & visual science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The interest in lipid nanoparticle (LNP)-mediated mRNA delivery significantly accelerated in the aftermath of the clinical success of mRNA-based COVID-19 vaccines. Validated as an effective and scalable platform, LNPs are now considered a cornerstone technology for the development of next-generation nucleic acid therapeutics. Recently, mRNA therapy entered the field of retinal gene therapy where it could treat retinal disorders contributing to the global numbers of vision impairment and blindness. While an historically driven focus on targeting outer retinal cells was initially in place, a shift toward delivery to the inner retina via intravitreal injection is ongoing. Yet, successful delivery is cumbersome since many nanocarriers are trapped at the inner limiting membrane (ILM). Therefore, this study enlightens the role of the ILM barrier with due consideration how fine-tuning LNP design impacts delivery after ILM disruption. For a standard LNP composition, we showed that ILM disruption is resulting in remarkable amounts of mRNA expression as opposed to an intact ILM. Based on an in-depth in vitro screening, the standard DSPC helper lipid was switched to DOPE to enhance expression levels and the percentage of PEGylation was adjusted to define LNP size. Despite the negative impact of elevated PEGylation on transfection efficiency in vitro, a significant boost in transfected retinal cells was noticed in an ex vivo setting due to improved penetration in the retina. In conclusion, we demonstrated that strategic design of LNP composition can boost LNP delivery beyond the ILM barrier and drive mRNA-LNP therapy to the retina forward.
Indexed as
Identifiers
41116066What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.